Allison Worldwide
Edit

Allison Worldwide

https://www.allisonworldwide.com/
Last activity: 01.06.2025
Active
Categories: AdTechCorporateGrowthLearnMediaMessangerPublicServiceSocialTechnology
We’re a global integrated marketing and communications consultancy dedicated to driving growth, innovation and positive change for clients, colleagues and communities. With a diverse range of expertise and a forward-looking mindset, we deliver game-changing results that make a lasting impact. Twitter.com/allisonww_ Instagram.com/Allisonworldwide
Followers
78.87K
Website visits
9.6K /mo.
Mentions
23
Employees: 501-1000

Mentions in press and media 23

DateTitleDescription
01.06.2025Powering Through the Storm: The Rise of EcoFlow's Portable SolutionsIn a world where power outages are becoming the norm, the need for reliable backup solutions has never been more pressing. Enter EcoFlow, a company that has emerged as a beacon of hope in the stormy seas of energy uncertainty. With its inno...
26.05.2025Charge Into The Cold: EcoFlow Launches EOFY SaleSYDNEY, May 26, 2025 /PRNewswire/ -- As Aussies prepare for winter getaways and school holidays road trips, EcoFlow is offering limited-time End of Financial Year (EOFY) savings on its popular DELTA series of portable power solutions and ac...
28.04.2025Mesoblast Appoints Corporate Finance Leader Lyn Cobley To BoardNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley ...
03.04.2025Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. TariffsNEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Governme...
02.04.2025Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart FailureNEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Admi...
13.03.2025Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United StatesNEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all f...
12.03.2025Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town HallNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive Silviu Itescu will deliver the Featured Pr...
26.02.2025Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This QuarterNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended ...
26.02.2025Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This QuarterFinancial Results and Operational Update for Half-Year Ended December 31, 2024 NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, t...
23.02.2025Dr. Gregory George MD PhD Joins Mesoblast BoardNEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s lar...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In